AJUNTAMENT D'ALCOI
Website
Generalitat Valenciana
Website
Ayuntamiento de Valencia
Website
Cicloplast
Website
Ayuntamiento de Onil
Website
Anarpla
Website
Ayuntamiento de Mislata
Website
nlWA, North London Waste Authority
Website
Ayuntamiento de Salinas
Website
Zicla
Website
Fondazione Ecosistemi
Website
PEFC
Website
ALQUIENVAS
Website
DIPUTACI� DE VAL�NCIA
Website
AYUNTAMIENTO DE REQUENA
Website
UNIVERSIDAD DE ZARAGOZA
Website
OBSERVATORIO CONTRATACIÓN PÚBLICA
Website
AYUNTAMIENTO DE PAIPORTA
Website
AYUNTAMIENTO DE CUENCA
Website
BERL� S.A.
Website
CM PLASTIK
Website
TRANSFORMADORES INDUSTRIALES ECOL�GICOS
INDUSTRIAS AGAPITO
Website
RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan?alginate matrix by combining layer-by-layer assembly with CaCl2 cross-linking for an effective treatment of inflammatory bowel diseases
Escherichia coli strain Nissle 1917 (EcN) has been widely shown to effectively treat inflammatory bowel diseases (IBDs). Unfortunately, after oral administration, EcN viability dramatically decreases due to severe environmental factors, including low gastric pH, temperature and osmotic pressure. To address these challenges and improve oral bio-availability, this study utilized layer-by-layer assembly (LbL) and ionic cross-linking with CaCl2 as a method of EcN encapsulation (GEcN). Upon examination, GEcN cells were shown to maintain their ability to grow and proliferate, but had a slightly longer stationary phase (10 h) relative to free EcN (4 h). When exposed to simulated gastric fluid (SGF), a higher number of GEcN cells survived up to 12 h when compared to the other groups. To assess the therapeutic effect of EcN encapsulation in vivo, a TNBS-induced colitis rat model was established. When compared with the oral administration of free EcN, GEcN exhibited a significantly enhanced anti-inflammatory effect. Furthermore, GEcN treatment showed a lower disease activity index (DAI), decreased pro-inflammatory cytokine expression (MPO, TNF-?, IL-6) and increased anti-inflammatory cytokine expression (IL-10). Additionally, rats that received GEcN had much higher ZO-1 expression levels. These results suggest that EcN encapsulation in a chitosan?alginate matrix when utilizing the LbL assembly with CaCl2 cross-linking can improve probiotic viability in a gastric environmental and thereby offer a more effective treatment for IBDs.
Graphical abstract» Author: Xiaoming Luo, Haixing Song, Jing Yang, Bin Han, Ye Feng, Yanbing Leng, Zhaoqiong Chen
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es